Abstract
Background Germline variants have traditionally been used for determining carrier status in heritable cancer families. However, studies are increasingly finding use of germline variants as therapeutic, diagnostic and prognostic biomarkers used to guide therapy decisions in cancer treatment.
Objectives To study the prevalence of mutation specific oncogenic biomarkers in the Indian population and analyze their presence across disease cohorts
Materials and Methods We annotate the IndiGen data obtained from whole genome sequencing of 1029 self-declared healthy Indian individuals with biomarker information obtained from the OncoKB knowledgebase, a repository of evidence-based information about somatic biomarkers and structural alterations in patient tumors.
Results In our study we have discovered 34 biomarker variants of therapeutic actionability across 16 genes linked with 23 unique drugs or drug combinations in 23 unique types of cancer disease in the Indian population. In all, we have found 52 biomarker variants with 172 different biomarker types including therapeutic, resistance, diagnostic, and prognostic. We establish that 4.3% of the Indian population are carriers of therapeutic, and 2.13% are carriers of both diagnostic as well as prognostic germline biomarkers. Finally, we also establish the prevalence of 42 biomarker variants across the 23 genes in both AD and AR modes of inheritance in the Indian population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the CNP-0007 project funded by the Council for Scientific and Industrial Research (CSIR-India)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Grant Sponsors: This work was supported by the CNP-0007 project funded by the Council for Scientific and Industrial Research (CSIR-India)
Conflict of interest: The authors declare that they have no conflict of interest.
Data Availability
All data produced in the present work are contained in the manuscript.